News & Events
Disc Medicine Announces Oral Presentation on Bitopertin at the 63rd American Society of Hematology Annual Meeting
CAMBRIDGE, Mass. (November 11, 2021) – Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for patients suffering from serious hematologic diseases, today announced that the company and its collaborators at Boston Children’s
More News
Disc Medicine Announces Underwritten Offering of Common Stock
WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery,...
read more
Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress
Updated analyses of data from AURORA and BEACON studies further demonstrate clinical activity of bitopertin across multiple measures of erythropoietic protoporphyria (EPP)...
read more
Disc Medicine to Participate in the Jefferies Global Healthcare Conference
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...
read more